| http://dbpedia.org/ontology/abstract
|
Marathon Pharmaceuticals LLC was a private … Marathon Pharmaceuticals LLC was a privately held biopharmaceuticals company focused on drugs for people with rare diseases. The Illinois-based company developed and manufactured therapeutics and brought them to market. It employed 100 people in four global locations. In 2017, PTC Therapeutics acquired rights to Marathon Pharmaceuticals' drug Emflaza (deflazacort) for $140 million after criticism about their plan to sell the drug at a list price of $89,000 per year to sufferers despite the fact that the same drug was available in Canada and the UK for around $1,000 per year.ada and the UK for around $1,000 per year.
|
| http://dbpedia.org/ontology/keyPerson
|
http://dbpedia.org/resource/Jeff_Aronin +
|
| http://dbpedia.org/ontology/locationCity
|
http://dbpedia.org/resource/Northbrook%2C_Illinois +
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Logo_of_Marathon_Pharmaceuticals.gif?width=300 +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
http://marathonpharma.com/ +
|
| http://dbpedia.org/ontology/wikiPageID
|
43080324
|
| http://dbpedia.org/ontology/wikiPageLength
|
11493
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1085809575
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Rare_disease +
, http://dbpedia.org/resource/The_Wall_Street_Journal +
, http://dbpedia.org/resource/Blood_disorders +
, http://dbpedia.org/resource/Northbrook%2C_Illinois +
, http://dbpedia.org/resource/Neurological_disorder +
, http://dbpedia.org/resource/Elijah_Cummings +
, http://dbpedia.org/resource/National_Organization_of_Rare_Disorders +
, http://dbpedia.org/resource/Category:Health_care_companies_based_in_Illinois +
, http://dbpedia.org/resource/Category:Manufacturing_companies_based_in_Chicago +
, http://dbpedia.org/resource/Deflazacort +
, http://dbpedia.org/resource/Food_and_Drug_Administration +
, http://dbpedia.org/resource/North_America +
, http://dbpedia.org/resource/Muscular_disorders%2C_atrophic +
, http://dbpedia.org/resource/Orphan_Drug_Act +
, http://dbpedia.org/resource/New_Drug_Applications +
, http://dbpedia.org/resource/Patient_advocacy +
, http://dbpedia.org/resource/Category:Pharmaceutical_companies_of_the_United_States +
, http://dbpedia.org/resource/Chicago_Tribune +
, http://dbpedia.org/resource/Bernie_Sanders +
, http://dbpedia.org/resource/Biopharmaceuticals +
, http://dbpedia.org/resource/Gastrointestinal_disorder +
, http://dbpedia.org/resource/Emflaza +
, http://dbpedia.org/resource/Jeff_Aronin +
, http://dbpedia.org/resource/Therapeutics +
, http://dbpedia.org/resource/Duchenne_muscular_dystrophy +
|
| http://dbpedia.org/property/areaServed
|
Worldwide
|
| http://dbpedia.org/property/founder
|
Robert Altman
|
| http://dbpedia.org/property/hqLocationCity
|
Northbrook, Illinois
|
| http://dbpedia.org/property/hqLocationCountry
|
USA
|
| http://dbpedia.org/property/industry
|
Pharmaceuticals
|
| http://dbpedia.org/property/keyPeople
|
Robert Altman
Jeffrey S. Aronin, former Chairman and CEO
|
| http://dbpedia.org/property/logo
|
File:Logo_of_Marathon_Pharmaceuticals.gif
|
| http://dbpedia.org/property/logoSize
|
200
|
| http://dbpedia.org/property/name
|
Marathon Pharmaceuticals
|
| http://dbpedia.org/property/products
|
Developed drugs for high-need, small patient populations, and late stage
|
| http://dbpedia.org/property/type
|
Private
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Infobox_company +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:Citation_needed +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Health_care_companies_based_in_Illinois +
, http://dbpedia.org/resource/Category:Pharmaceutical_companies_of_the_United_States +
, http://dbpedia.org/resource/Category:Manufacturing_companies_based_in_Chicago +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Marathon_Pharmaceuticals?oldid=1085809575&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Logo_of_Marathon_Pharmaceuticals.gif +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Marathon_Pharmaceuticals +
|
| http://xmlns.com/foaf/0.1/name
|
Marathon Pharmaceuticals
|
| owl:sameAs |
http://www.wikidata.org/entity/Q18352506 +
, http://yago-knowledge.org/resource/Marathon_Pharmaceuticals +
, https://global.dbpedia.org/id/mpBA +
, http://dbpedia.org/resource/Marathon_Pharmaceuticals +
, http://rdf.freebase.com/ns/m.0hqysns +
|
| rdf:type |
http://dbpedia.org/ontology/Company +
, http://www.wikidata.org/entity/Q24229398 +
, http://dbpedia.org/ontology/Organisation +
, http://schema.org/Organization +
, http://dbpedia.org/ontology/Agent +
, http://www.wikidata.org/entity/Q4830453 +
, http://www.wikidata.org/entity/Q43229 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#SocialPerson +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#Agent +
|
| rdfs:comment |
Marathon Pharmaceuticals LLC was a private … Marathon Pharmaceuticals LLC was a privately held biopharmaceuticals company focused on drugs for people with rare diseases. The Illinois-based company developed and manufactured therapeutics and brought them to market. It employed 100 people in four global locations. In 2017, PTC Therapeutics acquired rights to Marathon Pharmaceuticals' drug Emflaza (deflazacort) for $140 million after criticism about their plan to sell the drug at a list price of $89,000 per year to sufferers despite the fact that the same drug was available in Canada and the UK for around $1,000 per year.ada and the UK for around $1,000 per year.
|
| rdfs:label |
Marathon Pharmaceuticals
|
